Finance

Beta
Lists
CMPX:NASDAQ
Compass Therapeutics Inc.
$2.08
+0.48%
(+0.0100) 1D
$2.07
-0.48% (-0.0100)
After hours
Closed: Jun 26, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CMPX...
Open
$2.06
High
$2.12
Low
$2.02
Mkt. cap
374.58M
Avg. vol.
4.25M
Volume
7.61M
52-wk high
$6.88
52-wk low
$1.61
EPS
-$0.41
Beta
0.75
Shares outstanding
180.09M
No. of employees
39
Open
$2.06
High
$2.12
Low
$2.02
Mkt. cap
374.58M
Avg. vol.
4.25M
Volume
7.61M
52-wk high
$6.88
52-wk low
$1.61
EPS
-$0.41
Beta
0.75
Shares outstanding
180.09M
No. of employees
39
News stories
From sources across the web
About Compass Therapeutics Inc.
CEO-
Employees39
Founded2014
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Analyst ratings
Based on 11 analysts giving stock ratings to CMPX in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CMPX in the last 3 months.
Highest
Current $2.08
$24.00 (+1,053.85%)
Average
$9.38 (+350.96%)
Lowest
$4.00 (+92.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Biren Amin
Piper Sandler
Buy
Maintained
$4.00
+92.3%
06/01/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$6.00
+188.5%
06/01/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$24.00
+1,053.8%
06/01/2026
John Newman
Canaccord Genuity
Buy
Maintained
$7.00
+236.5%
05/22/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$6.00
+188.5%
05/09/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
-
-
05/06/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$8.00
+284.6%
05/06/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
05/05/2026
Sean McCutcheon
Raymond James
Hold
Downgraded
-
-
04/28/2026
Maury Raycroft
Jefferies
Buy
Maintained
$9.00
+332.7%
04/27/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$11.00
+428.8%
04/27/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$8.00
+284.6%
03/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
16.42M
12.83M
13.67M
13.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.65M
2.99M
4.32M
6.91M
Operating expense
21.07M
15.82M
17.99M
20.30M
Total operating expenses
21.07M
15.82M
17.99M
20.30M
Operating income
-21.07M
-15.82M
-17.99M
-20.30M
Other non operating income
-15.00K
-
-
-
EBT including unusual items
-19.88M
-14.26M
-15.72M
-18.32M
EBT excluding unusual items
-19.88M
-14.26M
-15.72M
-18.32M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-19.88M
-14.26M
-15.72M
-18.32M
Net profit margin
-
-
-
-
Earnings per share
-0.14
-0.08
-0.09
-0.10
Interest and investment income
1.20M
1.56M
2.27M
1.98M
Interest expense
-
-
-
-
Net interest expenses
1.20M
1.56M
2.27M
1.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.97M
-15.80M
-17.97M
-20.28M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

What's on your mind?
Give me an overview of CMPX
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more